Jeffrey M. Leiden

CIK: 0001242825

Transaction Breakdown

Open Market Buys (P)1 (2.8%)

High conviction signal

Open Market Sales (S)18 (50.0%)

Position reduction

Option Exercises (M)6 (16.7%)

Derivative conversions

Awards (A)5 (13.9%)

Compensation grants

Other (G, F, J, C, D, …)6 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ODTX

Odyssey Therapeutics, Inc.

Director

VRTX

VERTEX PHARMACEUTICALS INC / MA

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (36 total)

ODTX
Odyssey Therapeutics, Inc.
May 11, 2026
Tax Payment(F)
Indirect
17 shares at avg. $18.00$306
ODTX
Odyssey Therapeutics, Inc.
May 11, 2026
Exercise(M)
Indirect
3K shares-
ODTX
Odyssey Therapeutics, Inc.
May 11, 2026
Conversion(C)
Indirect
28.7K shares-
ODTX
Odyssey Therapeutics, Inc.
May 8, 2026
Purchase(P)
Direct
5K shares at avg. $20.00$100K
ODTX
Odyssey Therapeutics, Inc.
May 7, 2026
Award(A)
Stock Option (Right to Buy)
Direct
626.2K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 24, 2026
Tax Payment(F)
Direct
3.5K shares at avg. $485.11$1.7M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 18, 2026
Tax Payment(F)
Direct
3K shares at avg. $483.75$1.4M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Award(A)
Direct
8.3K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 22, 2026
Award(A)
Direct
9K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 4, 2025
Exercise(M)
Direct
1 shares at avg. $91.05$91.05
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
15.7K shares at avg. $452.20$7.1M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
10.4K shares at avg. $453.34$4.7M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
2.1K shares at avg. $455.22$942K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Exercise(M)
Direct
63.8K shares at avg. $86.52$5.5M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
4.5K shares at avg. $440.40$2.0M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
1.3K shares at avg. $441.26$582K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
2.5K shares at avg. $443.21$1.1M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
4.4K shares at avg. $444.36$1.9M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
7.9K shares at avg. $445.56$3.5M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
1.2K shares at avg. $447.05$515K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
2.3K shares at avg. $448.78$1.0M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
5.9K shares at avg. $449.84$2.6M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Dec 3, 2025
Sale(S)
Direct
5.8K shares at avg. $451.20$2.6M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Nov 14, 2025
Sale(S)
Direct
21.3K shares at avg. $441.35$9.4M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Nov 14, 2025
Exercise(M)
Direct
13.8K shares at avg. $91.05$1.3M

		Type	Shares	Price		Ownership
May 11, 2026	ODTX Odyssey Therapeutics, Inc.	Tax Payment(F)	17	$18.00	$306	Indirect
May 11, 2026	ODTX Odyssey Therapeutics, Inc.	Exercise(M)	2,963	-	$0	Indirect
May 11, 2026	ODTX Odyssey Therapeutics, Inc.	Conversion(C)	28,698	-	$0	Indirect
May 8, 2026	ODTX Odyssey Therapeutics, Inc.	Purchase(P)	5,000	$20.00	$100,000	Direct
May 7, 2026	ODTX Odyssey Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	626,220	-	-	Direct
Feb 24, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	3,547	$485.11	$1,720,685	Direct
Feb 18, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	2,964	$483.75	$1,433,835	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	8,269	-	$0	Direct
Jan 22, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	9,012	-	$0	Direct
Dec 4, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Exercise(M)	1	$91.05	$91	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	15,681	$452.20	$7,090,948	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	10,360	$453.34	$4,696,602	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,070	$455.22	$942,305	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Exercise(M)	63,781	$86.52	$5,518,332	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	4,469	$440.40	$1,968,148	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	1,320	$441.26	$582,463	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,469	$443.21	$1,094,285	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	4,352	$444.36	$1,933,855	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	7,899	$445.56	$3,519,478	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	1,152	$447.05	$515,002	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,320	$448.78	$1,041,170	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	5,880	$449.84	$2,645,059	Direct
Dec 3, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	5,809	$451.20	$2,621,021	Direct
Nov 14, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	21,330	$441.35	$9,413,996	Direct
Nov 14, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Exercise(M)	13,835	$91.05	$1,259,677	Direct

1-25 of 36 transactions

About LEIDEN JEFFREY M

LEIDEN JEFFREY M (SEC CIK 0001242825) files insider reports with the SEC as Director of Odyssey Therapeutics, Inc. (ODTX) and Executive Chairman of VERTEX PHARMACEUTICALS INC / MA (VRTX).

Signal8 holds 11 ownership filings by LEIDEN JEFFREY M (1 Form 3, 10 Form 4), filed between Sep 4, 2024 and May 11, 2026. Those filings report 36 transactions, from Aug 30, 2024 to May 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LEIDEN JEFFREY M's filings is in BOSTON, MA.

Recent filings by LEIDEN JEFFREY M

May 11, 2026: Tax withholding of ODTX shares (Form 4, code F).
May 11, 2026: Option exercise of ODTX shares (Form 4, code M).
May 11, 2026: Conversion of ODTX shares (Form 4, code C).
May 8, 2026: Open-market purchase of ODTX shares (Form 4, code P).
May 7, 2026: Grant or award of ODTX derivative securities (Form 4, code A).

Other insiders filing for Odyssey Therapeutics, Inc. (ODTX)

TPG GP A, LLC, Officer
Dimension Capital II, L.P., Director
SR ONE CAPITAL MANAGEMENT, LLC, 10% Owner
Haas Jason, Chief Financial Officer
Li Nan (LN), Director
SMITH IAN F, Director

How to read Form 4 transaction codes